Glenmark Pharmaceuticals announced its financial results for the first quarter ended June 30, 2026, reporting a consolidated revenue of ₹40,185 million, a 23.1% increase year-on-year. The company’s EBITDA grew by 38.6% to ₹8,048 million, with Profit After Tax (PAT) reaching ₹4,828 million. Strong performance was observed across key markets, particularly in North America and Emerging Markets.
Glenmark Pharmaceuticals Reports Strong Q1 FY27 Performance
Glenmark Pharmaceuticals Ltd. has announced its financial results for the first quarter of fiscal year 2027, which ended on June 30, 2026. The company reported a consolidated revenue of ₹40,185 million (approximately USD 425.1 million), marking a significant 23.1% increase compared to the ₹32,644 million (approximately USD 381.6 million) reported in the corresponding quarter of the previous fiscal year.
Key Financial Highlights
The company’s EBITDA for the quarter stood at ₹8,048 million, representing a substantial year-on-year growth of 38.6%. This resulted in an EBITDA margin of 20.03%. Profit After Tax (PAT) for the quarter was reported at ₹4,828 million, with a PAT margin of 11.8%.
Revenue Breakdown by Region
Revenue growth was broad-based across Glenmark’s key markets:
- India Formulations: Revenue increased by 15.5% YoY to ₹14,321 million.
- North America: Revenue grew by 41.1% YoY to ₹10,974 million, which includes deferred out-licensing income recognition for ISB 2001.
- Europe: Revenue saw a growth of 11.9% YoY to ₹7,472 million.
- Emerging Markets: Revenue increased by 27.7% YoY to ₹7,304 million.
Management Commentary
Glenn Saldanha, Chairman & Managing Director of Glenmark Pharmaceuticals Ltd., commented, “We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-to-market respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business.”
He further added, “The results reinforce the direction of Glenmark’s next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI’s pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value.”
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company focused on innovation and accessibility. With a strong presence in respiratory, dermatology, and oncology, the company operates across 80+ countries.
Source: BSE
